KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to 45.57%.

  • Eli Lilly's EBIT Margin rose 75200.0% to 45.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 43.16%, marking a year-over-year increase of 92600.0%. This contributed to the annual value of 35.92% for FY2024, which is 58600.0% up from last year.
  • According to the latest figures from Q3 2025, Eli Lilly's EBIT Margin is 45.57%, which was up 75200.0% from 45.13% recorded in Q2 2025.
  • Over the past 5 years, Eli Lilly's EBIT Margin peaked at 45.57% during Q3 2025, and registered a low of 21.46% during Q2 2021.
  • For the 5-year period, Eli Lilly's EBIT Margin averaged around 31.91%, with its median value being 30.4% (2021).
  • Per our database at Business Quant, Eli Lilly's EBIT Margin plummeted by -99300bps in 2023 and then soared by 115000bps in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's EBIT Margin stood at 29.44% in 2021, then dropped by -3bps to 28.44% in 2022, then rose by 13bps to 32.19% in 2023, then rose by 23bps to 39.44% in 2024, then increased by 16bps to 45.57% in 2025.
  • Its EBIT Margin stands at 45.57% for Q3 2025, versus 45.13% for Q2 2025 and 41.38% for Q1 2025.